CO2023011463A2 - Nuevos anticuerpos anti-cd24 - Google Patents
Nuevos anticuerpos anti-cd24Info
- Publication number
- CO2023011463A2 CO2023011463A2 CONC2023/0011463A CO2023011463A CO2023011463A2 CO 2023011463 A2 CO2023011463 A2 CO 2023011463A2 CO 2023011463 A CO2023011463 A CO 2023011463A CO 2023011463 A2 CO2023011463 A2 CO 2023011463A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibodies
- new anti
- pharmaceutical compositions
- present description
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
- G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021076075 | 2021-02-08 | ||
| CN202210088172 | 2022-01-25 | ||
| PCT/US2022/015711 WO2022170280A2 (en) | 2021-02-08 | 2022-02-08 | Novel anti-cd24 antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023011463A2 true CO2023011463A2 (es) | 2023-09-18 |
Family
ID=82741874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0011463A CO2023011463A2 (es) | 2021-02-08 | 2023-08-29 | Nuevos anticuerpos anti-cd24 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240052052A1 (https=) |
| EP (1) | EP4288099A4 (https=) |
| JP (1) | JP2024508672A (https=) |
| KR (1) | KR20230143177A (https=) |
| CN (1) | CN117412770A (https=) |
| AU (1) | AU2022217072A1 (https=) |
| CA (1) | CA3210934A1 (https=) |
| CO (1) | CO2023011463A2 (https=) |
| IL (1) | IL304898A (https=) |
| MX (1) | MX2023009238A (https=) |
| TW (1) | TW202241956A (https=) |
| WO (1) | WO2022170280A2 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024251257A1 (en) * | 2023-06-09 | 2024-12-12 | TJ Biopharma (Shanghai) Co., Ltd. | Anti-cd24 antibodies and uses thereof |
| GB202316777D0 (en) | 2023-11-01 | 2023-12-13 | Cambridge Entpr Ltd | New therapeutic use |
| WO2025101970A1 (en) * | 2023-11-08 | 2025-05-15 | Pheast Therapeutics, Inc. | Cd24 antibodies |
| WO2025128830A1 (en) * | 2023-12-12 | 2025-06-19 | The Methodist Hospital | Therapeutic lilrb regulation for treating neurological disorders |
| WO2025132836A1 (en) * | 2023-12-19 | 2025-06-26 | Pentixapharm Ag | Antibodies against cd24 |
| WO2025159754A1 (en) * | 2024-01-25 | 2025-07-31 | China Medical University | Therapeutic cd24 humanized monoclonal antibodies and anti-tumor translational use |
| WO2025218729A1 (en) * | 2024-04-17 | 2025-10-23 | TJ Biopharma (Shanghai) Co., Ltd. | Multifunctional molecules targeting cd24 |
| CN119161485B (zh) * | 2024-10-29 | 2026-03-24 | 上海中医药大学附属曙光医院 | 靶向GFRα3的抗体及其制备方法和在抗癌中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080002341A (ko) * | 2006-06-30 | 2008-01-04 | 재단법인서울대학교산학협력재단 | Ｃｄ２４를 표적으로 하는 암 억제방법 |
| WO2009063461A1 (en) * | 2007-11-14 | 2009-05-22 | The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center | Methods of treating cancer using anti cd24 antibodies |
| ES3012974T3 (en) * | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| AU2015229448B2 (en) * | 2014-03-11 | 2020-09-03 | The Board Of Trustees Of The Leland Stanford Junior University | Anti SIRP-alpha antibodies and Bi-specific Macrophage Enhancing antibodies |
| AU2015254257B2 (en) * | 2014-04-28 | 2021-02-25 | Medicinal Chemistry Pharmaceuticals, Co., Ltd. | Anti-MUC1 antibody or antigen-binding fragment of same, and use thereof |
| US20170158753A1 (en) * | 2014-06-25 | 2017-06-08 | Integrated Biotherapeutics, Inc. | Monoclonal antibodies directed against envelope glycoproteins from multiple filovirus species |
| WO2019222082A1 (en) * | 2018-05-14 | 2019-11-21 | Oncoimmune, Inc. | Anti-cd24 compositions and uses thereof |
| KR20210143868A (ko) * | 2019-03-26 | 2021-11-29 | 포티 세븐, 인코포레이티드 | 암 치료용 다중특이성 제제 |
| BR112021026133A2 (pt) * | 2019-06-25 | 2022-02-08 | Ichilov Tech Ltd | Anticorpo anti-cd24 e usos do mesmo |
-
2022
- 2022-02-08 CN CN202280013601.9A patent/CN117412770A/zh active Pending
- 2022-02-08 CA CA3210934A patent/CA3210934A1/en active Pending
- 2022-02-08 TW TW111104626A patent/TW202241956A/zh unknown
- 2022-02-08 KR KR1020237030578A patent/KR20230143177A/ko active Pending
- 2022-02-08 EP EP22750598.9A patent/EP4288099A4/en active Pending
- 2022-02-08 US US18/264,436 patent/US20240052052A1/en active Pending
- 2022-02-08 AU AU2022217072A patent/AU2022217072A1/en active Pending
- 2022-02-08 JP JP2023547592A patent/JP2024508672A/ja active Pending
- 2022-02-08 IL IL304898A patent/IL304898A/en unknown
- 2022-02-08 WO PCT/US2022/015711 patent/WO2022170280A2/en not_active Ceased
- 2022-02-08 MX MX2023009238A patent/MX2023009238A/es unknown
-
2023
- 2023-08-29 CO CONC2023/0011463A patent/CO2023011463A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3210934A1 (en) | 2022-08-11 |
| WO2022170280A3 (en) | 2022-09-09 |
| US20240052052A1 (en) | 2024-02-15 |
| KR20230143177A (ko) | 2023-10-11 |
| CN117412770A (zh) | 2024-01-16 |
| EP4288099A2 (en) | 2023-12-13 |
| WO2022170280A2 (en) | 2022-08-11 |
| MX2023009238A (es) | 2023-08-16 |
| TW202241956A (zh) | 2022-11-01 |
| EP4288099A4 (en) | 2025-09-17 |
| JP2024508672A (ja) | 2024-02-28 |
| AU2022217072A1 (en) | 2023-10-05 |
| IL304898A (en) | 2023-10-01 |
| AU2022217072A9 (en) | 2024-01-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023011463A2 (es) | Nuevos anticuerpos anti-cd24 | |
| CO2023018064A2 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| AR120883A1 (es) | Anticuerpos anti-fgfr2b | |
| CR20210326A (es) | Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor | |
| AR120886A1 (es) | Anticuerpos anti-fgfr2b | |
| CL2021000517A1 (es) | Anticuerpo etiquetado y/o fragmento del mismo que comprende un anticuerpo monoclonal o un fragmento del mismo, que se une específicamente a tau humano; ácido nucleico que lo codifica; vector; célula; método para producir anticuerpo; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| ES2527961T3 (es) | Anticuerpos monoclonales humanos para CD70 | |
| UY40829A (es) | Anticuerpos anti-phf-tau y sus usos | |
| CL2021001686A1 (es) | Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378) | |
| CY1123518T1 (el) | Ανθρωπινα αντισωματα enanti-tau | |
| MX2024010955A (es) | Nuevos anticuerpos anti-cd3 y usos de los mismos | |
| BR112022001368A2 (pt) | Proteínas que compreendem domínios de ligação ao antígeno de peptidase 2 relacionada à calicreína e seus usos | |
| PE20241349A1 (es) | Anticuerpos de union a cd3 | |
| CL2010000791A1 (es) | Anticuerpo monoclonales que se unen a integrina alfavbeta6 (7.7g5), composicion; hibridoma que lo produce (atcc pta-3899); usos para preparar un medicamento para tratar fibrosis, psoriasis, cancer y otros. (divisional solicitud n° 513-03) | |
| NI200900022A (es) | Anticuerpo especifico de prlr y usos del mismo | |
| PE20230389A1 (es) | Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas | |
| DOP2023000005A (es) | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas | |
| CO2023015915A2 (es) | Anticuerpos anti-ccr8 | |
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| CO2024003577A2 (es) | Anticuerpos del receptor antitransferrina y usos de los mismos | |
| CR11059A (es) | Novedosas moleculas de anticuerpos y acidos nucleicos que se enlazan con la proteina de tension fungica hsp90 | |
| MX2024015391A (es) | Molecula de union a antigeno que se une especificamente a dll3 y cd3, y su uso farmaceutico | |
| ECSP22097203A (es) | Anticuerpos dirigidos a un complejo que comprende hla-i no clásico y neoantígeno y sus métodos de uso | |
| CO2025007355A2 (es) | Anticuerpo anti-trem2 y usos del mismo | |
| CO2024007674A2 (es) | Anticuerpo anti-trem2 y usos del mismo |